• Bayer Q2 revenue rose 2.2% to EUR 10.87 billion; EBITDA before special items increased 1.9% to EUR 2.14 billion.
• Operating profit was EUR 827 million; net income swung to EUR 219 million as special charges narrowed to EUR 172 million, mainly litigation-related.
• Free cash flow widened to an outflow of EUR 371 million on higher litigation settlement payments; net financial debt rose to EUR 33.65 billion.
• Crop Science revenue climbed 3.5% to EUR 4.91 billion; EBITDA before special items more than doubled to EUR 902 million, lifting margin 3.9 percentage points to 18.4%.
• 2026 outlook was reaffirmed, with year-end net financial debt now seen at EUR 29-30 billion following a EUR 3 billion Apollo minority investment in a new LARC entity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.